AUG 7, 2026 · JOURNAL ARTICLE
Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients
Cancer
Population-based cohort study with adequate sample size showing protective mortality effects in HR+ breast cancer with post-diagnostic bisphosphonates, but observational design, lack of randomization, and conflicting results in TNBC subgroup limit strength.
Reported
Sample size (HR+ cohort)2260
Sample size (TNBC cohort)1436
Median follow-up (HR+)168.3 months